Ultragenyx Pharmaceutical vs United Therapeutics
RARE and UTHR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RARE and UTHR compare
United Therapeutics is the larger company, worth 16 times as much as Ultragenyx Pharmaceutical ($25.4B against $1.6B).
Ultragenyx Pharmaceutical grew revenue faster over the last twelve months (15.8% versus 1.9% for United Therapeutics).
United Therapeutics keeps more of each dollar of sales as profit, with a net margin of 38.6% compared with −71.8% at Ultragenyx Pharmaceutical.
United Therapeutics scores higher on the StockData Score (11 against 9 for Ultragenyx Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RARE | UTHR |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $25.4B |
| Share price | $16.08 | $591.17 |
| Change, 1 year | −52.0% | 28.1% |
| Change, 5 years | −79.7% | 194% |
| Beta (5Y) | 1.07 | 0.55 |
| Employees | 1,371 | 1,400 |
| StockData Score | ||
| Total score | 9 | 11 (better) |
| Valuation score | 1 | 1 |
| Growth score | 2 | 2 |
| Performance score | 1 | 5 (better) |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 22.3× |
| P/S | 2.2× (better) | 8.0× |
| P/B | – | 4.0× |
| EV/EBITDA | – | 16.4× |
| P/FCF | – | 29.2× |
| PEG | – | 0.97 |
| FCF yield | −27.9% | 3.4% (better) |
| Fair value | – | $473.57 |
| Margin of safety | – | −24.8% |
| Growth | ||
| Revenue growth (TTM) | 15.8% (better) | 1.9% |
| Revenue growth, 5Y average | 19.9% (better) | 16.5% |
| Net income growth (TTM) | – | −3.2% |
| EPS growth (TTM) | – | 0.34% |
| EPS growth, 5Y average | – | 19.3% |
| Profitability | ||
| Gross margin | – | 86.3% |
| Operating margin | −64.0% | 41.4% (better) |
| Net margin | −71.8% | 38.6% (better) |
| FCF margin | −60.5% | 27.2% (better) |
| Return on equity | – | 19.1% |
| Return on invested capital | – | 26.9% |
| Financial health | ||
| Interest coverage | – | 111× |
| Current ratio | 1.40 | 4.61 (better) |
| Altman Z-score | −5.73 | 23.40 (better) |
| Piotroski F-score | 5 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 7.9% |
| Shareholder yield | 0.00% | 7.9% (better) |
| Ownership | ||
| Held by institutions | 108% | 97.4% |
| Held by insiders | 4.0% | 9.1% |
| Insider net buying, 12 months | −$3.8M (better) | −$1.4B |
| Short interest, % of float | 25.0% | 4.7% |
Go deeper
- RARE stock overview
- RARE income statement
- RARE valuation and score
- UTHR stock overview
- UTHR income statement
- UTHR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.